Ho Etsahetse'ng le Hore na ke Hobane'ng ha e le Bohlokoa Hona Joale
Novo Nordisk e ile ea nka thepa e meraro ea botenya ea pele ho Kallyope: peptide e le 'ngoe ea kalafo le bonkgetheng ba babeli ba molek'hule e nyane, pepesitsoe ka 18 Loetse 2026 LinkedIn poso ea Jacob Petersen, Hlooho ea Novo ea lipatlisiso tsa lefats'e, ha ho na maemo a lichelete a senotsoeng (Tlaleho ea BioSpace mabapi le theko ea thepa, 21 Loetse 2026). Letlotlo le etellang pele, K-554, ke peptide e seng incretin hang ka beke e seng e loketse IND, Kallyope e sebetsa ho qala mohato 1 le ho lebella data halofo ea bobeli ea 2026 (Ho ngola tumellano ea Fierce Biotech, 18 Loetse 2026).
Tlhaloso e bohlokoa ho feta phatlalatso. Novo e reka mekhoa e fapaneng ea peptide hobane motheo oa eona oa khoebo o moqotetsane: thekiso e kopaneng ea Ozempic le Wegovy e fihlile hoo e ka bang $32 bilione selemong se fetileng, hoo e ka bang 67% ea thekiso e felletseng, ha khampani e ntse e tsoela pele 40% ea 'maraka oa ho theola boima ba' mele khahlano le Eli Lilly's 60%, ho latela likhakanyo tse ngata (CNBC ka February 2026 tlhahlobo ea boemo ba Novo, 25 Hlakola 2026). Novo e tataisitse 2026 thekiso le phaello ho theoha 5% ho 13%, eo e neng e tla ba eona ea pele ea selemo ea ho fokotseha ha thekiso ho tloha ka nako eo 2017. Ba nang le kabelo le bahlahlobisisi ba hatelletse mofuta ona oa ts'ebetso ea lipeipi, 'me koloi ea Kallyope e fihlile beke e le' ngoe ka mor'a hore Novo a ikemisetse ho etsa joalo $1.4 limilione tse likete ho Orbis Meriana bakeng sa li-macrocycles.
Key Takeaway： BioSpace le Fierce Biotech ka bobeli li khutlela morao ho phatlalatso e tšoanang ea Novo, Petersen's LinkedIn poso. Ke mohloli o le mong o baloang habeli, eseng ditiisetso tse pedi tse ikemetseng.
Ke Eng e Arohileng Mechanisms ea Peptide Tlhokahalo ea Discovery Chemistry
Lera leo la phethahatso le qala ka tlhaku, hobane mekhoa e fapaneng ea peptide e theko e tlaase ho e bitsa ebile e theko e boima ho e khetholla. A 2026 Tlhahlobo ea Frontiers ea li-peptide-receptor tse sa hlahlojoeng li thathamisa lethathamo la apelin, spex, METRNL, oxyntomodulin le PYY har'a li-receptors tse ntseng li hlahlojoa hanyane, 'me ke tlhahlobo ea baeloji, eseng palo ea mananeo. Ho fetola e 'ngoe ea tsona hore e be moetapele ho bolela moloko oa analog oa peptide o hahiloeng e le liphanele tse tsepamisitsoeng: litlhahlobo tsa alanine, litlhahlobo tsa boemo, li-truncations le li-control tsa scramble (Ho hlahisa Peptide: Li-platform tsa Laeborari le Maano a Phapang, 2019).
Boemo ba ho hloleha ha se hangata ha bo bolelele. Hydrophobicity e tsamaisoang ka tatellano le ho bokellana li holisa litlhoro le ho senya ho hlaphoheloa (PMC, 2008), mme maemong a thata haholo tlhoekiso ea HPLC ea li-peptide tse telele tsa hydrophobic e khutletse ka tlase 1% Khefutsa, ka li-peptide tsa Aβ ka bomong li ile tsa hlaphoheloa 0.7%. Multi-disulfide le cyclization-heavy tatelano eketsa cysteine-pairing heterogeneity, kahoo ketane e nepahetseng ea linear e ntse e ka fana ka kabo ea sehlahisoa e sa thabiseng (PMC, 2020).
|
Seo e se laolang |
|
|---|---|
|
Li-depsipeptides RP-HPLC bohloeki (sebaka %, 214-220 nm) |
Co-eluting litšila le mahetla aggregate |
|
LC-MS boitsebiso (shebiloeng vs boima ba khopolo-taba) |
Tatelano e fosahetseng kapa Theko e Tloaelehileng ea Peptide Synthesis kopanyo e hlolohetsoeng |
|
Tlhahlobo ea amino acid Tripeptide Synthesis |
Likahare tsa peptide li kenngoa ke metsi le letsoai |
|
Boikemisetso ba ho hanyetsa (TFA, acetate, chloride) |
Liphoso tsa ho leka-lekana ka bongata lipalong tsa dosing |
|
Endotoxin ea LAL (sele, phoofolo kapa mosebetsi o nyopa feela) |
Phello ea Endotoxin |
Bakeng sa Keletso: Setifikeiti sa morekisi se tlaleha se rometsoeng. Ho khetha analoge e latelang ho hloka sebopeho sa tlhoro, phoso ea bongata le counterion, hobane ba nka qeto ea hore na letoto lena lea khonahala kapa le se le ntse le kopane.
Seo Mananeo a Pele a Lokelang ho se Etsa Hona Joale
Tšoara mosebetsi oa analoge e le pina e bapileng, eseng e latellanang. Matha sehlopha se tsepamisitsoeng (alanine, maemo, li-truncation le li-scramble controls) hammoho le mosebetsi oa hau oa mantlha oa potency, hobane IND-itokisetso e bolela hore sephutheloana se tlameha ho khotsofatsa polokeho ea ntle le ts'ireletso le CMC / litebello tsa boleng ka nako e le 'ngoe., ho kenyeletsa botsitso, mekhoa ea ho hlahloba le histori ea batch (Peptide Li-peptide tse entsoeng ka tloaelo Trace, 2026-04-04). Litšoantšiso ke mohato oa lihlopha tse atisang ho chechisa morao ebe oa ikoahlaea: RP-HPLC kapa karolo ea sebaka sa UPLC ho 214-220 nm, LC-MS e hlokometsoe-khahlanong le-theoretical boima, tlhahlobo ea amino acid bakeng sa litaba tsa netweke, boikemisetso ba ho hanyetsa, le LAL feela moo lintho tse bonahalang li kopanang le lisele, liphoofolo kapa metsamao e tsoetsoeng ea mosebetsi. Notlela litokomane tsa boemo bo holimo pele ho nako ho e-na le ho li hlophisa bocha pele ho ketsahalo ea bohlokoahali.
Bakeng sa lihlopha tse hlokang tlhahiso ea analog ea peptide ka nako eo, Liphetoho tsa MOL li tšehetsa motsoako oa peptide oa tloaelo bakeng sa ho sibolloa ha pele ka tatellano ho fihlela 250 li-amino acid, bohloeki ho isa ho ≥98%., mg ho isa ho kg, lifomate tse hlano tsa analoge laebrari, ho feta 200 liphetoho, le Setifikeiti sa Tlhahlobo sa taelo e 'ngoe le e 'ngoe se nang le chromatogram ea HPLC le data ea spectral. Tšebeletso e Tloaelehileng ea Peptide Synthesis
Hlokomela: Sengoliloeng sena ke molemong oa tlhaiso-leseling ebile ha se keletso ea bongaka. Ikopanye le setsebi se tšoanelehang sa tlhokomelo ea bophelo pele u etsa liqeto tsa bongaka. MOL Changes e phatlalatsa e le morekisi oa peptide, le lintlha tsa bokhoni tse ka holimo li hlalosa litšebeletso tsa eona.
Lipotso Tse Botsoang Khafetsa
Ho bolela eng "non-incretin" ho nts'etsopele ea lithethefatsi tsa botenya?
Peptide ea non-incretin e besity e sebetsa ka tsela ea tlhaho ntle le GLP-1, GIP, kapa li-receptor tsa glucagon tseo lithethefatsi tse kang semaglutide le sepheo sa tirzepatide. Phapano eo e bohlokoa ka mabaka a mabeli. Ea pele, mamello: litla-morao tsa ka mpeng li hokahane haufi-ufi le ts'ebetso ea incretin receptor, kahoo mochine o fapaneng o ka qoba ho nyekeloa ke pelo le ho hlatsa tse tsamaisang ho khaotsa. Ea bobeli, bokhoni ba ho kopanya: e seng incretin agent e ka beoa kalafong e teng ea incretin ho fapana le ho qothisana lehlokoa le eona., e bula tšebeliso ea tlatsetso ho bakuli ba seng ba ntse ba le ho GLP-1.
IND-ready e hloka eng ho sephutheloana sa peptide CMC?
Ho fihlella ho faeloa ha Lithethefatsi tse Ncha tsa Patlisiso ho bolela k'hemistri, tlhahiso, 'me karolo ea taolo e tlameha ho theha tsela e ka hlahisoang hape, boemo bo hlalosoang ba bohloeki, le mokhoa oa ho hlahloba botsitso o bontšang botsitso. Sebopeho sa tlhahlobo ea peptide hangata se akaretsa boitsebahatso ka boima ba spectrometry, bohloeki ka HPLC, counterion le masalla solvent data, le lithuto tsa ho theola seriti. CMC le likarolo tseo e seng tsa bongaka tseo FDA e li lebelletseng li hlalositsoe ho tataiso ea setsi bakeng sa tlhahiso ea lipatlisiso..
Na mantsoe a tumellano ea Novo-Kallyope a tsejoa?
Che. Novo Nordisk ha e so hlahise lipehelo tsa lichelete tsa theko ea thepa, le tlaleho ea BioSpace mabapi le theko ea thepa e akaretsa sebopeho sa transaction ntle le theko. Ho ngoloa ha tumellano ea Fierce Biotech le eona e siea lipalo tse ka pele le tsa bohlokoa li sa boleloa. Tšoara boleng bofe kapa bofe bo khethehileng bo potolohang mecheng ea litaba tsa sechaba joalo ka ha bo sa netefatsoa.
Ke eng eo babali ba lokelang ho e shebella nakong e tlang?
Matsatsi a mabeli. Mokhahlelo 1 ya data bakeng sa thepa e fumanweng lebeletsoe ka halofo ea bobeli ea 2026, e tla ba teko ea pele ea 'nete ea hore na mochini oa non-incretin o fetolela ho tloha mefuteng ea pele ho ea ho mamello ea batho.. Nako e telele, lihlahisoa tsa semaglutide li boloka tšireletso ea 'maraka libakeng tse ngata ho fihlela lilemong tsa pele tsa 2030 empa li se li ntse li tobane le tlholisano ea patent linaheng tse khethiloeng joalo ka Canada., kahoo sebaka sa tlholisano bakeng sa ba kenoang ba arohaneng sea fokotseha ha phepelo e akaretsang e ntse e hola.
Qetello
Tumellano ea Novo-Kallyope e baloa hamolemo e le sesupo sa khaello: mekhoa e fapaneng ea peptide, eseng li-analogues tsa GLP-1 tse ntseng li eketseha, ke tseo balekane ba bangata ba lefang ho li fumana. Phello ea tatellano ea bobeli bakeng sa mananeo a pele ke hore botlolo bo tloha ho baeloji ho ea ts'ebetsong ea k'hemistri. Sepheo se tiisitsoeng sa non-incretin osity peptide ha se thuse lenaneo le sa khoneng ho pheta-pheta li-analogue ka potlako ho lekana ho araba lipotso tsa lona tsa SAR..
Seo se fetola sebopeho joalo ka mohato oa ho tlosa kotsi ho fapana le mokhoa o tlase. Mananeo a ngolang bohloeki, boitsebiso, 'me ho tsitsa ha lintho tse ngata esale pele ke bao data ea bona ea ka hare e pholohang ho hlahlojoa ha molekane kapa molaoli a botsa hore na sephetho se hlahisitsoe joang..
Kahoo lenane la litebelo le khuts'oane: pina eo mekhoa e fapaneng e hohelang litumellano tse latelang, le ho hlahloba hore na loop ea hau ea k'hemistri e ka tsamaisana le lebelo. Haeba karabo e tšepahalang e le “ha e so fihle,” mohato o latelang ke boitlamo bo fokolang. U ka kopa sephutheloana sa litokomane ho bona hore na QC ea boemo bo bongata e shebahala joang ha u sebetsa, kapa sebaka sa tlhahlobo ea ho khonahala bakeng sa tatelano e itseng pele u itlama ho tsela e kopaneng.
